Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 40

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Squamous cell carcinoma of head and neck+1

Not yet recruiting

Pharmacokinetic study of pembrolizumab and drug combination in patients with non‑small cell lung cancer or head and neck squamous cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Antoine Lacassagne

Idiopathic pulmonary fibrosis

Not yet recruiting

Safety and Tolerability of Metformin in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Placebo‑Controlled Phase II Study

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Philipps-Universitaet Marburg

Pulmonary arterial hypertension

Not yet recruiting

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Conjunctivitis allergic+2

Not yet recruiting

Efficacy and safety of allergenic extract of Olea europaea pollen polymerized with glutaraldehyde in patients with olive pollen allergy, including mild‑to‑moderate asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde
  • Sponsor:Inmunotek S.L.

Post-acute COVID-19 syndrome

Not yet recruiting

Rimonabant for Improving Cognitive Impairment in Patients with Post‑COVID‑19 Syndrome: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Respiratory syncytial virus infection

Not yet recruiting

Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
  • Sponsor:Pfizer Inc.

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Small cell lung cancer limited stage

Not yet recruiting

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmacosmos A/S

Non-small cell lung cancer

Not yet recruiting

Phase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oslo University Hospital HF

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Influenza

Not yet recruiting

Safety and immune response of OVX836C2 vaccine compared with drug combination in healthy adults with influenza

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Osivax

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.